Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148796 · ClinicalTrials.gov registry record · Phase 2
Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 822
- Enrollment target
NCT02148796: Completed Phase 2 study, sponsored by University of Arizona.
NCT02148796 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 822 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (518% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02148796, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 822 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.
Primary Outcome
The time to the occurrence of the first WLRI episode in the observation period while not receiving study drug
Interventions
- OTHER Placebo
- DRUG Broncho-Vaxom (BV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
What the finished NCT02148796 record still lists
NCT02148796 is an interventional study that assigns participants to a tested intervention. The registered 822 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (518% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02148796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02148796 about?
NCT02148796 is a clinical study titled "Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness". The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.
What is the current status of trial NCT02148796?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 822 participants. The study started on 2017-01-01. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT02148796?
The interventions under investigation include: Placebo (OTHER), Broncho-Vaxom (BV) (DRUG).
Who is sponsoring clinical trial NCT02148796?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02148796's enrollment target sits among peer trials
822 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07357389 · 822 participants · NA
Virtual Reality for ICU Delirium Prevention
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI